Innerwell combines personalized guidance from licensed therapists with cutting-edge psychedelic medicine. Now serving patients in Arizona, California, Colorado, Connecticut, Florida, New Jersey, New York, Ohio, Oregon, Utah, Texas, Virginia, Minnesota and Washington State. || Innerwell Reflections

Innerwell Reflections

Reflections

Find a Clinician by State

Find a Psychiatrist

Find a Therapist

Find Ketamine Treatment

Find EMDR Therapy

EMDR

Ketamine Treatment

Psychedelic Integration

psychiatry

therapy

mental-health

arizona-mental-health

california-mental-health

colorado-mental-health

connecticut-mental-health

Delaware

florida-mental-health

georgia-mental-health

idaho-mental-health

illinois-mental-health

iowa-mental-health

Kentucky

maine-mental-health

massachusetts-mental-health

michigan-mental-health

minnesota-mental-health

montana-mental-health

Nebraska

nevada-mental-health

new-hampshire-mental-health

new-jersey-mental-health

new-york-mental-health

north-carolina-mental-health

ohio-mental-health

oregon-mental-health

pennsylvania-mental-health

tennessee-mental-health

texas-mental-health

utah-mental-health

vermont-mental-health

virginia-mental-health

washington-mental-health

wisconsin-mental-health

 Personalized Mental Health Support from Wyoming Specialists

About

Refer a Patient to Innerwell

Work With Us

Reviews

Why Innerwell

Contact

Affiliate Program

Ketamine for Depression

Ketamine for Anxiety

Ketamine for PTSD

Ketamine for Postpartum Depression

Welcome! What service are you primarily interested in?

Innerwell Privacy Policy

Terms & Conditions

Innerwell Telehealth and Informed Consent

Notice of Privacy Practices

Page Not found. It's okay, we all get a little lost from time to time. 

Find Therapy & Counseling Services Near Me

KBS, Inc. and its affiliates (“Innerwell”) provide a platform that connects medical professionals with individuals. Innerwell does not control or direct the activity of the medical professionals providing care through the platform. Innerwell does not provide medical advice and nothing on the platform should be considered medical advice.

You've done the research on antidepressants, tried therapy, maybe explored multiple medications without finding relief. Now you're reading about ketamine, and the questions are piling up. Is it actually safe? Will you lose control during treatment? Could you become dependent?

These concerns make sense. You've probably been burned before by treatments that promised more than they delivered. The idea of "psychedelic therapy" might feel like a leap into the unknown.

In clinical trials of low-dose ketamine for treatment-resistant depression, 50–70% of people respond, achieving at least a 50% reduction in symptoms. For people who haven't found relief through conventional treatments, those numbers represent real hope.

The bottom line: Ketamine therapy has a favorable safety profile when administered with proper medical oversight. Side effects are temporary, usually resolving within 90 minutes to a few hours. Safety depends on both the medication's properties and the quality of screening, supervision, and therapeutic support.

Ketamine therapy uses sub-anesthetic doses of ketamine to treat depression, anxiety, and other mental health conditions. These doses are far lower than surgical applications.

Originally developed as an anesthetic, ketamine gained psychiatric interest after researchers discovered its rapid antidepressant effects. Improvements can appear within hours rather than the 4–6 weeks traditional antidepressants require.

Clinicians prescribe ketamine for depression and anxiety off-label. The FDA has approved ketamine as an anesthetic and esketamine (Spravato) for treatment-resistant depression in adults, but racemic ketamine for psychiatric conditions is prescribed off-label.

Ketamine therapy takes several forms: FDA-approved esketamine nasal spray administered in certified clinics, off-label IV ketamine at specialized facilities, and sublingual tablets with telehealth supervision.

Professional medical guidelines position ketamine as an option for people with treatment-resistant depression, not a first-line approach. VA and DoD guidelines recommend ketamine or esketamine as an augmentation option for adults whose depression hasn't responded to adequate medication trials.

Ketamine operates through a fundamentally different mechanism than traditional antidepressants. While SSRIs and SNRIs adjust serotonin levels gradually over weeks, ketamine works much faster.

Animal and human studies indicate ketamine's effects stem from a cascade of brain changes. Researchers continue mapping the exact pathways, but here's what the current science shows:

Stage 1: Releasing the brake. Ketamine blocks NMDA receptors on certain inhibitory brain cells, removing the "brake" that depression appears to place on neurons.

Stage 2: The glutamate surge. With the brake lifted, your brain releases glutamate, the primary chemical signal that activates neurons and promotes communication between brain cells.

Stage 3: Growth factor release. The glutamate surge triggers a cascade of cellular events. Brain cells begin forming new connections, a process called synaptogenesis. Ketamine also activates BDNF (brain-derived neurotrophic factor), which acts like fertilizer for brain cells. BDNF helps neurons grow, survive, and form connections that support improved mood.

Stage 4: New connections form. These new neural pathways can help bypass the damaged circuits that depression has created. Markers of neuroplasticity appear to remain elevated for several days after a single ketamine dose in many studies.

The rapid synaptic remodeling explains why ketamine can provide relief when months of SSRIs haven't. New connections form within hours.

Understanding ketamine's side effects helps you know what to expect. Most are temporary and resolve quickly.

Dissociation, the feeling disconnected from your body, occurs in about 28% of people and typically resolves within two hours. Many find it therapeutically valuable because it creates distance from entrenched thought patterns.

Physical symptoms like headache, dizziness, and nausea affect roughly one in four people. These usually resolve within 24 hours.

Blood pressure elevation occurs temporarily during treatment. Providers monitor vital signs throughout, and levels return to baseline within hours. Cardiovascular screening before treatment matters for this reason.

What Does Improvement Actually Look Like?

Clinical trials measure symptom reduction on standardized scales. But what does a 50–70% response rate feel like in daily life?

Within hours or days, many people notice shifts that feel almost unfamiliar after months or years of depression. The intrusive thoughts quiet down. Tasks that felt insurmountable start feeling possible again: answering an email, taking a shower, calling a friend.

For some, the change is dramatic. For others, it's subtle at first. You realize you laughed at something, or you didn't dread waking up this morning.

Many people describe it as finally having access to parts of themselves that depression had locked away. The motivation that used to come naturally starts returning. Planning for the future feels possible instead of pointless. Small pleasures register again: a good meal, a conversation with a friend.

Mayo Clinic reports symptom relief can last weeks after treatment.

Ketamine therapy is not right for everyone, and long-term data are still emerging. Here's what we know and what remains uncertain.

In pooled clinical trial data, fewer than 5% of people discontinue due to adverse effects. Some reviews cite rates below 1%. In therapeutic settings at sub-anesthetic doses, serious complications remain uncommon.

In long-term studies of intranasal esketamine for treatment-resistant depression, follow-up extending to about 4.5 years has not revealed new major safety signals under monitored clinical use.

Most long-term safety data come from intranasal esketamine programs in monitored clinic settings. Caution is still warranted when generalizing to all ketamine protocols.

Bladder and urinary concerns have been documented in chronic, high-dose recreational ketamine users, not in therapeutic protocols. Medical dosing is far lower and less frequent than patterns associated with these complications.

Cognitive effects have not been consistently observed in therapeutic use. Some studies suggest ketamine may actually improve cognitive function as depression lifts.

In properly supervised medical settings, addiction risk is low. A systematic review found no documented cases of ketamine dependence originating in clinical treatment programs, though long-term data remain limited.

The key protective factors: sub-anesthetic dosing, spaced treatments (not daily use), medical oversight, limited medication supply, and integration with therapy. The therapeutic approach differs fundamentally from recreational use patterns.

Ketamine therapy requires careful screening. Not everyone is a candidate.

Cardiovascular conditions with weakened blood vessels (aneurysms, brain hemorrhage)

Active psychotic disorders with current hallucinations or delusions

Relative contraindications require careful evaluation:

Uncontrolled high blood pressure (must be managed first)

Severe heart disease (requires cardiovascular evaluation)

History of psychosis (even if not currently active)

Before starting treatment, you'll receive comprehensive screening that assesses cardiovascular health, psychiatric history, medication interactions, and contraindications.

How Does Ketamine Compare to Other Treatments for Safety?

Ketamine's common side effects are typically short-lived around each dosing session. SSRIs often cause side effects (such as sexual dysfunction or weight changes) that can persist for as long as treatment continues.

Ketamine has not been associated with the chronic sexual dysfunction, weight gain, or emotional blunting commonly seen with many SSRIs. Unlike SSRIs, ketamine doesn't cause a classic antidepressant discontinuation syndrome between supervised treatments, though you can still experience symptom return between doses.

SSRIs have decades of long-term safety data, while ketamine data extends to about 4.5 years. Available clinical data and expert reviews indicate that ketamine is generally safe to use alongside many SSRIs under medical supervision, though careful monitoring is still recommended.

In a large randomized trial comparing ketamine with ECT for treatment-resistant depression, ketamine showed comparable response rates (55% vs. 41%) with a different side-effect profile. ECT requires anesthesia and can cause memory effects. Ketamine's effects are typically temporary and don't require general anesthesia.

The FDA has raised concerns about compounded ketamine products used without adequate medical supervision. These warnings target services with minimal oversight, not all at-home treatment.

Supervision quality matters more than location.

A large prospective study found telehealth-supported sublingual ketamine to be safe and effective, with low adverse event rates. Response and remission rates were consistent with clinic-administered ketamine. Safety depends critically on telehealth supervision quality, emergency protocols, proper screening, and trained support person presence. Direct head-to-head safety comparisons between settings are still limited.

Why Does the Therapeutic Approach Matter?

Expert consensus and early data suggest ketamine therapy works best when embedded in a comprehensive care plan that includes psychotherapy and follow-up support. The medication opens a door. Therapy helps you walk through it.

Integration sessions help you process the experiences and insights that emerge during treatment. A skilled mental health professional helps you connect what you felt during ketamine sessions to patterns in your daily life.

The combination matters because ketamine creates a window of neuroplasticity. During this window, your brain becomes more adaptable. Old thought patterns become easier to interrupt. New responses to stress, new ways of relating to yourself and others, become possible in ways they weren't before. Therapy helps direct that adaptability toward meaningful growth.

What does treatment actually look like? And can you access effective care without rearranging your life around clinic visits?

Innerwell delivers at-home ketamine therapy paired with licensed psychotherapist support.

This isn't ketamine dropped off with minimal supervision. The program operates with real-time telehealth supervision and comprehensive clinical oversight, addressing the concerns the FDA has raised about inadequately supervised at-home treatment.

Comprehensive screening before treatment begins: cardiovascular evaluation, psychiatric history review, medication interaction check, and contraindication assessment.

Licensed clinicians overseeing every session. Master's or Doctoral-level therapists with specialized training through partnerships like Fluence Training.

Real-time telehealth monitoring. Clinicians are present via video during your session, monitoring for adverse reactions and providing support.

Required support person. A trusted adult must be present during and after treatment.

Therapeutic support built in. Preparation and integration sessions help translate insights into lasting improvement.

Accessible pricing. Treatment costs as low as $54/session with insurance.

In Innerwell's program data, people report a 69% reduction in depression symptoms and a 60% reduction in anxiety symptoms after 10 weeks, with 87% reporting improvement within four weeks and an average satisfaction rating of 4.7/5 stars.

Take our free assessment to see if ketamine therapy might be right for you.

Ketamine therapy has accumulated substantial safety evidence over more than a decade of clinical research. Side effects are typically temporary, serious complications are rare with proper oversight, and long-term data show no new major safety signals.

Treatment safety depends on both ketamine's pharmacology and the quality of screening, dosing, and supervision. Proper medical oversight and therapeutic integration determine outcomes.

Will I feel out of control during ketamine treatment?

No. While about 28% of people experience dissociation—feeling temporarily disconnected from your body—you remain aware throughout and effects resolve within two hours. Clinicians can adjust dosing to manage intensity. Most describe the experience as unusual but manageable, not frightening.

No. You should not drive or operate heavy machinery for at least 24 hours after treatment. Arrange transportation in advance and have your support person available to help if needed.

Can I drink alcohol or take benzodiazepines with ketamine?

You should avoid alcohol for 24 hours before and after treatment. Benzodiazepines can affect the ketamine experience and may reduce therapeutic benefit. Discuss all medications with your clinician during screening.

Initial treatment typically involves sessions 2–3 times per week for several weeks, then transitions to maintenance as needed. The spaced, limited dosing in therapeutic protocols differs significantly from patterns associated with recreational misuse.

What happens if I have an adverse reaction during treatment?

With Innerwell, a licensed clinician monitors your session via telehealth and can intervene immediately. You'll also have a trained support person physically present. Emergency protocols are in place, and your clinician can adjust dosing or discontinue treatment if needed.

How does ketamine compare to traditional antidepressants for safety?

Ketamine's common side effects are typically short-lived around each dosing session, while SSRI side effects can persist throughout treatment. SSRIs have longer safety track records (decades vs. about 4.5 years for ketamine), but available ketamine data shows no major safety signals under medical supervision.

Ketamine therapy has a favorable safety profile with proper oversight. Learn about side effects, risks, and what makes treatment safe.

Is Ketamine Therapy Safe? Common Concerns Answered

Introduction

What Is Ketamine Therapy?

How Does Ketamine Work for Depression?

What Are the Short-Term Side Effects?

What Are the Long-Term Risks?

Who Should Not Receive Ketamine?

Is At-Home Ketamine Therapy Safe?

At-Home Ketamine Therapy with Innerwell

The Bottom Line

You've probably encountered conflicting information about ketamine therapy. One source calls it a party drug. Another warns about addiction. A third claims it's a miracle cure. If you've been researching treatment-resistant depression, these contradictions make an already difficult decision harder.

You're not alone. Millions of people with depression don't respond adequately to traditional antidepressants, and many of them are trying to separate fact from fiction about alternatives like ketamine.

The bottom line: Most of what circulates about ketamine therapy is outdated, incomplete, or applies to recreational use rather than supervised medical treatment. When administered properly, ketamine is an evidence-based option with response rates often in the 40–70% range. It works through a completely different mechanism than traditional antidepressants, and that difference matters.

Ketamine therapy involves administering controlled doses of ketamine under medical supervision to treat depression, anxiety, PTSD, and other mental health conditions. The doses used are subanesthetic, far lower than those used for surgical anesthesia or recreational purposes.

Two main clinical approaches exist. FDA-approved esketamine (Spravato) is a nasal spray requiring healthcare provider observation and 2-hour post-administration monitoring through REMS protocols. Off-label racemic ketamine is delivered via IV, intramuscular injection, or sublingual tablets.

Clinical guidelines describe ketamine-based therapies for treatment-resistant depression, typically defined as inadequate response to at least two adequate antidepressant trials. Ketamine isn't a first-line treatment. It's an option when other approaches haven't worked.

Traditional antidepressants like SSRIs target serotonin. They require 4–8 weeks to work because therapeutic effects depend on gradual changes in receptor sensitivity.

Ketamine operates through a fundamentally different system. It targets NMDA receptors in the glutamate system, producing antidepressant effects within hours to days. The speed matters.

Stage 1: Releasing the brake. Ketamine blocks NMDA receptors on inhibitory brain cells, removing the neurological brake that normally suppresses activity in mood-regulating circuits.

Stage 2: The glutamate surge. With the brake released, your brain releases glutamate, its primary excitatory neurotransmitter. The glutamate surge activates AMPA receptors.

Stage 3: Growth factor release. AMPA activation triggers release of Brain-Derived Neurotrophic Factor (BDNF), a protein essential for neuronal growth.

Stage 4: New connections form. Studies suggest ketamine rapidly promotes synapse formation in mood-related circuits, which may underlie its fast antidepressant effects.

For someone living with treatment-resistant depression, this mechanism can mean feeling functional again within days instead of waiting months for another antidepressant trial.

What Are the Most Common Myths About Ketamine Therapy?

Fact: Ketamine is not an opioid. Johns Hopkins confirms it works through NMDA receptors in the glutamate system, not opioid receptors. The confusion may stem from ketamine's use as an anesthetic, but it has a completely different mechanism and risk profile than opioids like morphine or fentanyl.

Myth #2: "It just gets you high and masks symptoms"

Fact: This theory has been "debunked" according to Mayo Clinic. Ketamine produces measurable neuroplastic changes that outlast any acute effects. Brain imaging studies show ketamine promotes new synaptic connections in mood-regulating regions. These are structural changes, not just symptom masking.

Myth #3: "Ketamine therapy is highly addictive"

Fact: A scoping review of 65 studies found no misuse or dependence in professionally supervised treatment for treatment-resistant depression. Context matters: medical doses, clinical oversight, and structured protocols fundamentally change the safety profile compared to recreational use. Ketamine is classified as a Schedule III controlled substance, meaning it has recognized abuse potential, but supervised medical treatment is different from recreational use.

Fact: Single doses often produce effects lasting 1–2 weeks in people who respond. Maintenance protocols can extend benefits over a year or more for some. The duration varies by individual, but "temporary" doesn't mean "brief."

Myth #5: "Ketamine causes permanent brain damage"

Fact: This concern comes from studies of heavy recreational abuse at high doses over extended periods. Research at therapeutic doses has generally not found evidence of persistent cognitive decline. Medical ketamine uses controlled doses in supervised settings, a fundamentally different exposure pattern.

Myth #6: "At-home ketamine is unsafe or unregulated"

Fact: The FDA has warned about compounded ketamine products used without proper medical oversight. But at-home ketamine with appropriate clinical supervision, including psychiatric evaluation, dosing protocols, monitoring, and integration support, is a legitimate treatment model. The key is choosing a provider with licensed clinicians and comprehensive safety protocols, not minimal screening and follow-up.

Fact: Ketamine isn't a one-and-done cure. Most protocols involve 6–8 sessions over 2–3 weeks for initial treatment, followed by maintenance sessions as needed. Many people who respond see noticeable improvement within the first few sessions, but a substantial minority don't respond even after a full induction series. Lasting benefit often requires combining ketamine with therapy to translate neuroplastic changes into new thought patterns and behaviors.

Clinical trials demonstrate substantial efficacy for treatment-resistant populations:

Response rates often in the 40–70% range, depending on protocol

Rapid onset within 24 hours of first dose in many cases

In one inpatient trial, JAMA research reported 44% remission rates with adjunctive ketamine infusions

Significant reduction in suicidal ideation demonstrated in randomized controlled trials according to Nature research

In a large NEJM trial of nonpsychotic treatment-resistant depression, ketamine achieved a 55% response rate compared to 41% for electroconvulsive therapy.

Not everyone responds. Some people complete a full treatment series without meaningful improvement. But for many who haven't found relief elsewhere, ketamine represents a genuinely different approach.

Clinical trials measure symptom reduction on standardized scales. But what does it feel like in practice?

People often describe it as the volume turning down. The constant noise of dread or emptiness doesn't vanish entirely, but it quiets enough to function. You might notice you can get out of bed without the usual negotiation. A conversation with a friend doesn't feel like performing. Activities that once brought some pleasure start to register again.

Small tasks that felt insurmountable become manageable. The mental fog that made concentration difficult starts to lift. You might find yourself looking forward to something for the first time in months.

The experience is less about euphoria and more about remembering what a baseline sense of functioning felt like before depression made you forget.

According to the FDA label, dissociation, dizziness, nausea, temporary blood pressure increases, and sedation are among the most common adverse reactions of ketamine therapy. Most dissociative and blood-pressure-related effects occur around dosing and typically resolve the same day.

Bladder effects: Long-term heavy recreational use has been associated with bladder problems. At therapeutic doses with appropriate monitoring, this risk is much lower, but providers should track any urinary symptoms.

Blood pressure: Temporary increases during treatment require monitoring, especially for people with cardiovascular concerns.

Dissociation: The dissociative experience during treatment can feel unsettling for some people, though many find it tolerable or even helpful for processing difficult emotions.

Proper screening, monitoring, and follow-up substantially reduce these risks. The key is working with a provider who takes safety seriously, not one focused on minimal oversight.

Careful screening matters. Ketamine therapy may not be appropriate for people with:

Uncontrolled hypertension or significant cardiovascular disease

Active psychosis or a history of psychotic disorders

If any of these apply, you'll need specialist evaluation before considering ketamine. A thorough screening process protects you and ensures treatment is both safe and appropriate.

Ketamine promotes neuroplasticity. New synaptic connections form in mood-regulating brain regions. But that neuroplasticity window is most valuable when you use it intentionally.

The medication opens a door. Therapy helps you walk through it.

Evidence-based answers about ketamine therapy safety, addiction risk, and how it works. Learn what's true—and what isn't—about this treatment option.

Reflections

Is Ketamine Therapy Safe? Common Concerns Answered

Ketamine Therapy Myths and Facts: What You Should Know

Ketamine Therapy for Aggression: Complete Guide

Ketamine Therapy for Schizophrenia: What You Need to Know

Prozac Alternatives: Medications, Natural Options & More

Ketamine Therapy Disqualifiers: Eligibility Guide

Top Lexapro Alternatives: Medications, Therapy, and What Actually Works